CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
$0M01FY2000RRNIH
University Of Michigan At Ann Arbor, Ann Arbor MI
Investigators
Linked publications & trials
Paper 38314748Paper 38198070Paper 37685568Paper 37330506Paper 37234789Paper 36609358Paper 35776183Paper 34096894Paper 33560208Paper 33002231Paper 32980045Paper 32603751Paper 31505070Paper 31404238Paper 31282733Paper 31190621Paper 30984083Paper 30927986Paper 30747308Paper 30678194Paper 30557093Paper 29993318Paper 29212847Paper 28960081Paper 28869987Paper 28643023Paper 28451964Paper 28122876Paper 27979912Paper 27943008Paper 27549341Paper 27542969Paper 27434583Paper 27420606Paper 27335285Paper 27142670Paper 27009936Paper 26908360Paper 26597192Paper 26536870Paper 26456676Paper 26346867Paper 26313512Paper 26030112Paper 25794949Paper 25643011Paper 25419511Paper 25401485Paper 25139294Paper 25037617Paper 24956500Paper 24920421Paper 24802413Paper 24760534Paper 24729646Paper 24656865Paper 24613295Paper 24524706Paper 24516231Paper 24448547Paper 24415732Paper 24409005Paper 24219913Paper 24218993Paper 24104772Paper 24084768Paper 24077027Paper 24066347Paper 24008570Paper 23923994Paper 23727086Paper 23572495Paper 23559261Paper 23546553Paper 23530302Paper 23489677Paper 23445216Paper 23377559Paper 23362085Paper 23344473Paper 23321443Paper 23298715Paper 23291148Paper 23282046Paper 23222413Paper 23178053Paper 23090351Paper 23076013Paper 22980963Paper 22965589Paper 22935481Paper 22933587Paper 22847786Paper 22742082Paper 22688849Paper 22687333Paper 22658574Paper 22577025Paper 22554719Paper 22516527
Abstract
This is a phase I study seeking the maximally tolerated dose of gemcitabine delivered concurrent with a standard course of radiation for patients with unresectable head and neck tumors. Plasma levels and tumor incorporation of gemcitabine, as well as tumor nucleotide pools will be measured in order to gain a better understanding of the mechanisms by which gemcitabine may enhance radiation antitumoral activity in vivo.
View original record on NIH RePORTER →